Segments - Schedule of Segment Reporting Expenses (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Segment loss	$ 23,862		$ 45,592		$ 45,634	$ 104,527
Reconciliation of segment loss
Interest and other (income) expense, net	(1,491)		(3,101)		(3,223)	(6,669)
Interest expense	0		809		0	1,608
Net loss	22,371	$ 20,040	43,300	$ 56,166	42,411	99,466
Reportable Segment
Operating expenses:
Program expense including clinical trial and third-party contracting costs	9,595		1,292		15,180	2,728
Bexotegrast - clinical trial and third party contracting costs	(311)		13,359		(1,088)	34,948
Employee-related expenses - research and development (excluding stock-based compensation)	2,926		10,344		6,463	20,830
General and administrative costs (excluding stock-based compensation)	4,413		8,947		10,074	19,236
Other segment items	7,239		11,650		15,005	26,785
Segment loss	23,862		45,592		45,634	104,527
Reconciliation of segment loss
Interest and other (income) expense, net	(1,491)		(3,101)		(3,223)	(6,669)
Interest expense	0		809		0	1,608
Net loss	$ 22,371		$ 43,300		$ 42,411	$ 99,466